"Hematinics" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents which improve the quality of the blood, increasing the hemoglobin level and the number of erythrocytes. They are used in the treatment of anemias.
| Descriptor ID |
D006397
|
| MeSH Number(s) |
D27.505.954.502.543
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Hematinics".
Below are MeSH descriptors whose meaning is more specific than "Hematinics".
This graph shows the total number of publications written about "Hematinics" by people in this website by year, and whether "Hematinics" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 |
| 2002 | 1 | 0 | 1 |
| 2004 | 1 | 0 | 1 |
| 2005 | 2 | 0 | 2 |
| 2006 | 0 | 2 | 2 |
| 2007 | 3 | 0 | 3 |
| 2008 | 4 | 1 | 5 |
| 2010 | 4 | 1 | 5 |
| 2013 | 3 | 2 | 5 |
| 2014 | 2 | 1 | 3 |
| 2015 | 0 | 1 | 1 |
| 2016 | 2 | 0 | 2 |
| 2017 | 3 | 0 | 3 |
| 2018 | 1 | 0 | 1 |
| 2020 | 3 | 0 | 3 |
| 2021 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Hematinics" by people in Profiles.
-
Medical costs and associated racial/ethnic and sex disparities in erythropoiesis-stimulating agent use: anemia management under the Medicare reimbursement policy. J Manag Care Spec Pharm. 2021 Aug; 27(8):1142-1152.
-
Improving oncology biosimilar launches in the EU, the USA, and Japan: an updated Policy Review from the Southern Network on Adverse Reactions. Lancet Oncol. 2020 12; 21(12):e575-e588.
-
End of an era of administering erythropoiesis stimulating agents among Veterans Administration cancer patients with chemotherapy-induced anemia. PLoS One. 2020; 15(6):e0234541.
-
End of an era for erythropoiesis-stimulating agents in oncology. Int J Cancer. 2020 05 15; 146(10):2829-2835.
-
Investigating Serious Adverse Drug Reactions in Patients Receiving Erythropoiesis-Stimulating Agents: A Root Cause Analysis Using the "ANTICIPATE" Framework. Am J Ther. 2018 Nov/Dec; 25(6):e670-e674.
-
Reply to A.M. Zeidan et al. J Clin Oncol. 2017 10 01; 35(28):3265.
-
Tale of Two Erythropoiesis-Stimulating Agents: Utilization, Dosing, Litigation, and Costs of Darbepoetin and Epoetin Among South Carolina Medicaid-Covered Patients With Cancer and Chemotherapy-Induced Anemia. J Oncol Pract. 2017 06; 13(6):e562-e573.
-
Effects of the US Food and Drug Administration Boxed Warning of Erythropoietin-Stimulating Agents on Utilization and Adverse Outcome. J Clin Oncol. 2017 Jun 10; 35(17):1945-1951.
-
Peginesatide for the treatment of anemia due to chronic kidney disease - an unfulfilled promise. Expert Opin Drug Saf. 2016 Oct; 15(10):1421-6.
-
Consensus on the Existence of Functional Erythropoietin Receptors on Cancer Cells. JAMA Oncol. 2016 Jan; 2(1):134-6.